ROBERT JAY HOPKINS

Summary

Publications

  1. ncbi request reprint Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults
    Robert J Hopkins
    Clinical Development, Emergent BioSolutions, Gaithersburg, MD, USA Electronic address
    Vaccine 32:2217-24. 2014
  2. pmc Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers
    Robert J Hopkins
    Emergent BioSolutions Inc, Gaithersburg, MD, USA
    Vaccine 31:3051-8. 2013

Detail Information

Publications2

  1. ncbi request reprint Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults
    Robert J Hopkins
    Clinical Development, Emergent BioSolutions, Gaithersburg, MD, USA Electronic address
    Vaccine 32:2217-24. 2014
    ..This study was conducted to support licensure of a post-exposure prophylaxis indication for BioThrax(®) (anthrax vaccine adsorbed) concurrent with antimicrobials for individuals exposed to aerosolized anthrax spores...
  2. pmc Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers
    Robert J Hopkins
    Emergent BioSolutions Inc, Gaithersburg, MD, USA
    Vaccine 31:3051-8. 2013
    ..No AEs of special interest (autoimmune events) were observed in the study. Further studies of doses and dosing regimens are planned to assess the immunogenicity and reactogenicity of AV7909...

Research Grants2

  1. Anthrax Immune Globulin to Prevent & Treat Anthrax: Clinical Development
    Robert Hopkins; Fiscal Year: 2006
    ..More information about Emergent BioSolutions and its subsidiaries can be found at www.ebsi.com. ..
  2. BioThrax Schedule Optimization for Post-Exposure Prophylaxis of Anthrax
    Robert Hopkins; Fiscal Year: 2006
    ....